Stockscreener 앱 받기
1.62
0.00%
0.00
시간 외 거래:
1.59
-0.03
-1.85%
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial - TipRanks
OKYO Pharma executive chairman linked entity acquires additional shares on NASDAQ - Investing.com
OKYO Pharma executive chairman increases stake with share purchase - Proactive financial news
OKYO Pharma (NASDAQ: OKYO) chair adds shares as NCP drug advances - Stock Titan
OKYO Pharma founder-linked firm buys 10,119 more shares - Stock Titan
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3 - TipRanks
OKYO Pharma director acquires additional shares on NASDAQ - Investing.com
OKYO Pharma (NASDAQ: OKYO) director boosts stake with 5,000-share purchase - Stock Titan
A director just increased his OKYO Pharma stake to 31,201 shares - Stock Titan
OKYO Pharma announces director stock purchase - Proactive financial news
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress - TipRanks
OKYO Pharma director acquires 30,980 shares, increases total holding - Investing.com
OKYO Pharma Limited Reports Share Acquisition by Chief Development Officer and Advances in Neuropathic Corneal Pain Therapy Development - Quiver Quantitative
Biotech executive buys more OKYO stock, lifting stake to 108,920 shares - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial By Investing.com - Investing.com India
OKYO Pharma (OKYO) Chief Development Officer reports stock and option holdings - Stock Titan
OKYO Pharma (OKYO) director Cerrone reports 10.5M common-share stake on Form 3 - Stock Titan
Urcosimod Phase 2 NCP data show QoL gains, OKYO Pharma (OKYO) plans Phase 2b/3 - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial - Investing.com
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain - The Manila Times
OKYO Pharma Reports New Phase 2 Data Demonstrating - GlobeNewswire
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial - Proactive financial news
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February - MarketBeat
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.2%Time to Buy? - MarketBeat
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
OKYO Pharma prices public offering at $1.85/share to raise up to $20M - MSN
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option - TipRanks
OKYO Pharma (OKYO) lifts equity proceeds to $22M after option exercise - Stock Titan
Market Wrap: Is OKYO Pharma Limited a turnaround story2026 Momentum Check & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Geopolitics Watch: Will Coeptis Therapeutics Holdings Inc. Equity Warrant benefit from rate cutsQuarterly Portfolio Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Published on: 2026-03-07 08:54:47 - baoquankhu1.vn
Setup Watch: Can OKYO Pharma Limited maintain sales growthQuarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn
Market Rankings: Is OKYO Pharma Limited stock trending bullishIndex Update & Capital Protection Trade Alerts - baoquankhu1.vn
OKYO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress - The Manila Times
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 - Proactive Investors
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026 - TipRanks
OKYO Pharma's Urcosimod Selected for Presentation at ARVO 2026 Annual Meeting Following Positive Phase 2a Trial Results for Neuropathic Corneal Pain Treatment - Quiver Quantitative
OKYO (Nasdaq: OKYO) to present Fast Track NCP therapy data at ARVO 2026 - Stock Titan
Analysts Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Target Price at $6.00 - Defense World
Piper Sandler Initiates Coverage on OKYO Pharma (NASDAQ:OKYO) - Defense World
OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler - MarketBeat
Piper Sandler initiates OKYO Pharma stock with Overweight rating By Investing.com - Investing.com Nigeria
How OKYO Pharma Limited stock compares to industry benchmarksWeekly Trade Review & Daily Volume Surge Signals - mfd.ru
CEO Moves: Is OKYO Pharma Limited a turnaround story2025 Pullback Review & Weekly High Return Stock Forecasts - baoquankhu1.vn
How interest rate cuts could boost OKYO Pharma Limited stockJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - mfd.ru
Piper Sandler initiates OKYO Pharma stock with Overweight rating - Investing.com South Africa
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Piper Sandler Initiates Coverage on OKYO Pharma With Overweight Rating, $7 Price Target - marketscreener.com
Big Money Moves: How interest rate cuts could boost OKYO Pharma Limited stock2025 Investor Takeaways & Entry and Exit Point Strategies - mfd.ru
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - VisionMonday.com
Small cap wrap: Trust Stamp, HIVE Digital Technologies, OKYO Pharma... - Proactive financial news
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain - Proactive financial news
1.20%
0.06%
자본화:
|
볼륨(24시간):